Oppenheimer Holdings, Inc. assumed coverage on shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) in a research note released on Monday. The firm issued a buy rating and a $27.00 price target on the biotechnology company’s stock. Oppenheimer Holdings also issued estimates for Heron Therapeutics’ Q3 2017 earnings at ($0.83) EPS, Q4 2017 earnings at ($0.88) EPS, FY2017 earnings at ($3.49) EPS, Q1 2018 earnings at ($0.87) EPS, Q2 2018 earnings at ($0.81) EPS, Q3 2018 earnings at ($0.66) EPS, Q4 2018 earnings at ($0.49) EPS, FY2018 earnings at ($2.81) EPS, FY2019 earnings at ($0.55) EPS, FY2020 earnings at $1.46 EPS and FY2021 earnings at $3.30 EPS.
Several other analysts also recently weighed in on the company. Zacks Investment Research raised Heron Therapeutics from a hold rating to a buy rating and set a $14.00 target price for the company in a report on Wednesday, July 12th. Aegis reissued a buy rating and issued a $33.00 target price on shares of Heron Therapeutics in a report on Tuesday, July 18th. Cantor Fitzgerald set a $31.00 target price on Heron Therapeutics and gave the company a buy rating in a report on Friday, October 20th. BidaskClub raised Heron Therapeutics from a sell rating to a hold rating in a report on Saturday, August 26th. Finally, Noble Financial reissued a buy rating and issued a $24.00 target price on shares of Heron Therapeutics in a report on Friday, October 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the company. The stock currently has an average rating of Buy and an average price target of $28.36.
Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.90) by $0.10. The firm had revenue of $8.51 million during the quarter, compared to analysts’ expectations of $4.53 million.
ILLEGAL ACTIVITY NOTICE: “Heron Therapeutics, Inc. (HRTX) Research Coverage Started at Oppenheimer Holdings, Inc.” was originally reported by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this piece of content on another publication, it was illegally stolen and republished in violation of international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://sportsperspectives.com/2017/11/02/heron-therapeutics-inc-hrtx-research-coverage-started-at-oppenheimer-holdings-inc.html.
Several hedge funds have recently modified their holdings of the company. Janus Henderson Group PLC purchased a new position in shares of Heron Therapeutics during the 2nd quarter worth approximately $78,134,000. Vanguard Group Inc. raised its stake in shares of Heron Therapeutics by 11.8% during the 2nd quarter. Vanguard Group Inc. now owns 2,096,465 shares of the biotechnology company’s stock worth $29,036,000 after buying an additional 221,362 shares in the last quarter. State Street Corp raised its stake in shares of Heron Therapeutics by 30.7% during the 1st quarter. State Street Corp now owns 1,787,678 shares of the biotechnology company’s stock worth $26,822,000 after buying an additional 420,113 shares in the last quarter. Rubric Capital Management LP raised its stake in shares of Heron Therapeutics by 6.3% during the 2nd quarter. Rubric Capital Management LP now owns 1,700,000 shares of the biotechnology company’s stock worth $23,545,000 after buying an additional 100,000 shares in the last quarter. Finally, Balyasny Asset Management LLC raised its stake in shares of Heron Therapeutics by 2.1% during the 2nd quarter. Balyasny Asset Management LLC now owns 1,221,403 shares of the biotechnology company’s stock worth $16,916,000 after buying an additional 24,688 shares in the last quarter.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.